Jump to section
To harness the power of technology and data to shape innovations that bring the right care to every person, no matter where they are.
Data provides the means for analysts to predict all manner of life events, including using health data to predict patient deterioration. However, aggregating and analyzing data is such a time-consuming process that it is almost impossible to get a holistic view of a patient's health and predict the best courses of action.
Biofourmis provides an ML-driven healthcare predictive analytics platform, aggregating patient data and using ML to analyze the data, streamline connections between patients and care teams, and ultimately predict health outcomes. The platform integrates directly with existing software for care providers, pharmacies, patients, and healthcare payers, helping to reduce healthcare costs by increasing data transparency, optimizing care plans, and reducing re-admission rates.
Whilst the company faces competition from other ML-driven healthcare data analysis platforms, Biofourmis stands out by providing its services to all parties, not just healthcare providers - an approach which provides the benefits of AI-assisted healthcare whilst reducing existing communication friction. Having surpassed unicorn status in 2022, the company has been focussed on expanding operations, including by scaling its virtual care offerings and securing further high-value partnerships.
Kirsty
Company Specialist at Welcome to the Jungle
Aug 2022
$20m
SERIES D
Apr 2022
$300m
SERIES D
This company has top investors
Kuldeep Singh Rajput
(CEO)Board Member and Advisor at Neuroglee Therapeutics. Experience as a Researcher for MIT Media Lab, and was a Research Scholar for the Singapore Institute for Neurotechnology (SINAPSE) and the National University of Singapore from 2014 to 2016.
Mark Niu
(Chief of InfoSec & Privacy Officer)Graduated with a PhD in Chemical Engineer from the National University of Singapore in 2016. Co-founded Biofourmis in 2016 as CPO, but has since changed roles.
Maulik Majmudar, M.D.
(Chief Medical Officer)Research Fellow in Cardiovascular Medicine and Associate Director of the Healthcare Transformation Lab for Massachusetts General Hospital from 2011 to 2018. Medical Advisor for Amazon from 2018 to 2021, and for HILABSINC since 2016.